Αρχική World News Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive,... World News Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC Από Ogkologos - 30 Ιανουαρίου, 2026 600 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... 18 Φεβρουαρίου, 2021 20.° Aniversario de Cancer.Net: Celebramos Nuestra Misión de Brindar Información Confiable... 16 Νοεμβρίου, 2022 Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... 25 Φεβρουαρίου, 2021 For Children with Retinoblastoma, Disparities Seen across the Globe 12 Μαρτίου, 2020 Φόρτωση περισσοτέρων HOT NEWS ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical... New lung cancer treatment combo approved on NHS in England Cancer in My Community: Providing Supportive Care in Serbia “No Person With Cancer or Survivor Should Ever Feel Alone”: A...